PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Callizot and Appert Collin Group Art Unit: 1614

Serial No.: 10/551,395 Examiner: Royds, Leslie A.

Filed: September 29, 2005 Docket No.: 1386/22

Confirmation No.: 3252

For: USE OF PIPERAZINE PHENOTHIAZINE DERIVATIVES, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF, IN THE MANUFACTURE OF A MEDICAMENT WITH NEUROPROTECTOR AND/OR NEUROTROPHIC SETERS ON ONE AND/OR DESIGNATION.

NEUROTROPHIC EFFECTS ON CNS AND/OR PNS

RESPONSE TO RESTRICTION/ELECTION REQUIREMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This is responsive to the Restriction/Election Requirement dated April 8, 2009, having a 1-month term for Response that will expire on May 8, 2009. Favorable consideration is respectfully requested in view of the following Election and Remarks.

RESTRICTION PRESENTED

The claims have been restricted in the following manner. The U.S. Patent and Trademark Office (hereinafter the "Patent Office") has required that claims 13-14 and 16-18 be restricted to a single disclosed specie of compound of formula (I) from those specifically claimed in claim 13.